Tumor News and Research

RSS

Colorectal cancer identified by its unique microbial fingerprint

Colorectal cancer is unique in having its own microbial 'fingerprint' – according to new research from the University of East Anglia.

3 Sep 2025

Novel vascularized cancer-on-a-chip model reflects the microenvironment of liver tumors

Dr. Vadim Jucaud's lab at the Terasaki Institute has developed a human vascularized liver cancer-on-a-chip model to evaluate vessel remodeling and cell death in response to embolic agents.

3 Sep 2025

New drug dismantles cancer cell powerhouse to halt tumor growth

Researchers at MUSC Hollings Cancer Center have discovered a potentially powerful weapon in the fight against head and neck cancers.

2 Sep 2025

Breakthrough discovery reveals treatable form of familial mesothelioma

Researchers working independently at the University of Hawaii Cancer Center and the National Cancer Institute have discovered, and validated, a new variant of mesothelioma that may lead to more successful treatments.

2 Sep 2025

Platelets found to mop up DNA fragments and improve early cancer detection

Platelets are probably best known for their role in blood clotting, making scabs and related, if less salubrious, contributions to heart attacks and strokes.

2 Sep 2025

Plant-derived carotenoid found to boost immune response against cancer

In a new study, researchers from the University of Chicago discovered that zeaxanthin, a plant-derived carotenoid best known for protecting vision, may also act as an immune-boosting compound by strengthening the cancer-fighting activity of immune cells.

2 Sep 2025

MicroRNA panels show promise for improving prostate cancer diagnosis

Prostate cancer is highly heterogeneous, ranging from slow-growing tumors to aggressive, life-threatening disease.

2 Sep 2025

Dormant tumor cells targeted to reduce breast cancer relapse

A first-of-its-kind, federally funded clinical trial has shown it's possible to identify breast cancer survivors who are at higher risk of their cancer coming back due to the presence of dormant cancer cells and to effectively treat these cells with repurposed, existing drugs.

2 Sep 2025

Glutamate receptors found to drive pediatric brain tumor development

The most common type of brain tumor in children, pilocytic astrocytoma (PA), accounts for about 15% of all pediatric brain tumors.

1 Sep 2025

Cancer-related nerve injury triggers inflammation and immunotherapy resistance

Cancer cells can break down the protective covers around nerves, causing nerve injury that triggers chronic inflammation leading to immune exhaustion and eventual resistance to immunotherapy, according to new research from The University of Texas MD Anderson Cancer Center.

1 Sep 2025

Genomic clues uncover early origins of multiple myeloma

A new study maps out the timeline of DNA damage for multiple myeloma, the second most common blood cancer.

1 Sep 2025

Study provides evidence for a causal genetic link between prostate cancer and urothelial carcinoma

Prostate cancer is among the most common cancers in men and a leading cause of cancer-related deaths. With improved detection and therapies, survival rates have risen, but this progress comes with a new concern: the risk of secondary primary malignancies.

1 Sep 2025

Scientists discover molecular brake that limits T cell attack on tumors

In a discovery that could expand the array of current cancer immunotherapy treatments, scientists at Harvard Medical School have identified a new molecular brake that hinders the ability of T cells to attack tumors.

1 Sep 2025

How plant compounds could target Alzheimer’s disease from multiple angles

This review highlights how dietary polyphenols modulate Alzheimer’s disease biology through antioxidant, anti-inflammatory, and multi-target mechanisms, supported by in-silico docking analyses. Despite promise, challenges in bioavailability and brain delivery remain key hurdles to clinical translation.

31 Aug 2025

New off-the-shelf immunotherapy for metastatic kidney cancer could help improve outcomes

UCLA researchers have developed a new kind of immunotherapy that uses specially engineered immune cells equipped with built-in weapons to attack kidney cancer tumors and reprogram their protective environment - all without the need to customize treatment for each individual patient.

29 Aug 2025